Menon Vin has officially reported his role as Co-Chief Executive Officer of Apimeds Pharmaceuticals US, Inc. This filing is significant as it highlights his leadership position within the company, particularly in the context of the pharmaceutical industry, which is currently facing various regulatory and market challenges.

Background

Apimeds Pharmaceuticals US, Inc. operates in the pharmaceutical preparations sector. The company is incorporated in Delaware and has its fiscal year ending on December 31. The recent filing was made on November 2, 2026, and is classified under the SEC's 1934 Act.

What the Filing Says

The filing indicates that Menon Vin holds no securities directly but has ownership of 484,775 shares of common stock through Series A Convertible Preferred Stock. This stock is set to convert automatically into common shares upon certain conditions being met, specifically stockholder approval and NYSE American's approval of a new listing application.

Impact

This update may affect corporate governance and shareholder dynamics at Apimeds Pharmaceuticals. It also highlights the importance of leadership roles in guiding companies through the complexities of the pharmaceutical market.

What's Next

The filing does not say what happens next.

Details of the Convertible Preferred Stock

The Series A Convertible Preferred Stock held by Menon Vin is structured to convert into common stock at a ratio of 1:20, meaning each share of the preferred stock will convert into 20 shares of common stock. This conversion is contingent upon stockholder approval and the approval of a new listing application by NYSE American. Notably, the preferred stock does not have an expiration date, providing flexibility in the timing of the conversion.

Company Information

Apimeds Pharmaceuticals US, Inc. is classified under the Standard Industrial Classification (SIC) code 2834, which pertains to pharmaceutical preparations. The company is incorporated in Delaware and operates from its business address located at 100 Matawan Rd, Suite 325, Matawan, NJ, with a business phone number of 848-201-5010. The fiscal year for the company concludes on December 31, aligning its reporting period accordingly.

Reporting Owner's Address

Menon Vin's reported address is 30 Waterside Plaza #36, New York, NY 10010. This location serves as his official residence as listed in the SEC filing.

Additional Context

The filing does not provide information regarding Menon Vin's previous roles or experience in the pharmaceutical industry, nor does it detail any future plans or strategic initiatives for Apimeds Pharmaceuticals US, Inc. Furthermore, there is no mention of other executives or board members in the filing, which could provide insight into the company's leadership structure.